- Home
- YHC vs TXMD Comparison
YHC vs TXMD Comparison
Compare YHC & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHC
- TXMD
- Stock Information
- Founded
- YHC 2021
- TXMD 2008
- Country
- YHC United States
- TXMD United States
- Employees
- YHC N/A
- TXMD N/A
- Industry
- YHC Beverages (Production/Distribution)
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- YHC Consumer Staples
- TXMD Health Care
- Exchange
- YHC Nasdaq
- TXMD Nasdaq
- Market Cap
- YHC 12.3M
- TXMD 12.8M
- IPO Year
- YHC N/A
- TXMD N/A
- Fundamental
- Price
- YHC $1.15
- TXMD $1.30
- Analyst Decision
- YHC Strong Buy
- TXMD
- Analyst Count
- YHC 2
- TXMD 0
- Target Price
- YHC $5.00
- TXMD N/A
- AVG Volume (30 Days)
- YHC 113.4K
- TXMD 738.0K
- Earning Date
- YHC 03-31-2025
- TXMD 03-28-2025
- Dividend Yield
- YHC N/A
- TXMD N/A
- EPS Growth
- YHC N/A
- TXMD N/A
- EPS
- YHC N/A
- TXMD N/A
- Revenue
- YHC $2,272,001.00
- TXMD $1,596,000.00
- Revenue This Year
- YHC $120.06
- TXMD $605.07
- Revenue Next Year
- YHC $72.42
- TXMD $1.11
- P/E Ratio
- YHC N/A
- TXMD N/A
- Revenue Growth
- YHC 158.05
- TXMD N/A
- 52 Week Low
- YHC $0.40
- TXMD $0.70
- 52 Week High
- YHC $2.45
- TXMD $2.75
- Technical
- Relative Strength Index (RSI)
- YHC N/A
- TXMD 68.51
- Support Level
- YHC N/A
- TXMD $0.95
- Resistance Level
- YHC N/A
- TXMD $1.08
- Average True Range (ATR)
- YHC 0.00
- TXMD 0.09
- MACD
- YHC 0.00
- TXMD 0.02
- Stochastic Oscillator
- YHC 0.00
- TXMD 49.30
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.